MARKET

ONTX

ONTX

Onconova
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3999
-0.0081
-1.99%
Opening 13:41 01/24 EST
OPEN
0.4169
PREV CLOSE
0.4080
HIGH
0.4200
LOW
0.3855
VOLUME
7.84M
TURNOVER
--
52 WEEK HIGH
4.826
52 WEEK LOW
0.1027
MARKET CAP
55.48M
P/E (TTM)
-0.1102
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ONTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ONTX News

  • Onconova shares rise after company regains rights to drug in China
  • American City Business Journals.19h ago
  • Onconova regains rigosertib rights in China; shares up 17% premarket
  • seekingalpha.23h ago
  • Onconova Therapeutics Regains Rigosertib Rights in Greater China
  • GlobeNewswire.1d ago
  • Onconova Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market
  • GlobeNewswire.01/03 18:27

More

Industry

Pharmaceuticals
-1.50%
Pharmaceuticals & Medical Research
-1.64%

Hot Stocks

Name
Price
%Change

About ONTX

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.
More

Webull offers Onconova Therapeutics Inc (ONTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.